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Abstract: Background: An association of insulin use and risk of cancer has been reported but evidence is conflicting and 
methodological issues have been identified. 
Objective: To summarize results regarding insulin use and cancer risk by a systematic review and meta-analysis of cohort 
and case-control studies examining risk of cancer associated with insulin use in patients with diabetes. 
Data Sources: Systematic literature search in 5 databases: PubMed, Embase, Web of Science, Scopus and Cochrane 
Library. 
Study Eligibility Criteria (PICOS): Population: diabetes patients. Exposure: Users of any exogenous insulin. Comparison: 
Diabetes patients with or without use of antidiabetic drugs. Outcome: Any incident cancer. Study Design: Cohort and 
case-control studies.  
Results: 42 eligible studies examined risk of any cancer and 27 site-specific cancers. Results of individual studies were 
heterogeneous. Meta-analyses were significant for: Insulin vs No Insulin: Increased risk for pancreas, liver, kidney, 
stomach and respiratory cancer, decreased risk for prostate cancer. Insulin vs Non-Insulin Antidiabetics: Increased risk for 
any, pancreatic and colorectal cancer. Glargine vs Non-Glargine Insulin: Increased risk for breast cancer, decreased risk 
for colon cancer. 
Limitations: Few studies available for most cancer sites and exposure contrasts, and few assess effect of dose and duration 
of exposure. Methodological issues in several studies. Availability of confounders. 
Conclusions: Insulin use was associated with risk of cancer at several sites. Cautious interpretation of results is warranted 
as methodological issues and limitations in several of the included studies have been identified. Choice of study design 
may have a profound effect on estimated cancer risk. 
Keywords: Cancer risk, diabetes mellitus, insulin, neoplasm, meta-analysis, systematic review. 
INTRODUCTION 
Rationale 
 Associations between diabetes mellitus and increased 
risk of cancer at several sites have been established [1-3]. It 
remains unclear whether this relationship between diabetes and 
cancer is direct, e.g. because of hyperglycemia, or if it is 
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mediated through underlying biologic factors like insulin 
resistance and hyperinsulinemia, or if it is indirectly linked 
through common risk factors such as obesity. Insulin is a 
growth factor, and it is biologically plausible that high levels of 
endogenous insulin or exposure to exogenous, administered 
insulin could stimulate neoplastic growth [4, 5]. In recent years, 
several studies have reported modification of cancer risk by use 
of specific antidiabetic drugs. A decreased risk associated with 
use of metformin has been reported in meta-analyses while 
results for thiazolidinedione are not conclusive [6-8]. Results 
from observational studies published in 2009 raised concerns of 
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a link between insulin use and risk of cancer, but the results of 
these initial studies were inconclusive and conflicting [9-11]. 
Publication of many studies assessing risk of cancer at different 
sites from other data sources has ensued. Several of these 
observational studies have been hampered by methodological 
issues and did not take into account dose, duration and timing of 
insulin exposure or lacked information on important 
confounders [10, 12-14]. In addition, most studies have been too 
small for robust quantification of cancer risk, specially for 
examining cancer sites individually. The ability to study cancer 
at specific sites individually is important because cancer is not a 
homogenous disease and different pathways are involved in the 
aetiology for different subtypes of cancer [2]. 
 Existing evidence from randomized controlled trials (RCT) 
is also limited. Two meta-analyses of RCT data published in the 
wake of the initial observational studies published in 2009 did 
not find an increased risk for insulin glargine and detemir [15, 
16]. However, these studies were rather small for studying a 
rare event such as cancer and were of limited duration. A larger 
RCT study with 6 years duration that assessed insulin glargine 
exposure and had cancer incidence as a secondary outcome 
reported no increased risk of cancer overall and no significant 
results for site-specific cancers [17]. However, the general 
limitations of RCTs regarding representativeness of the study 
population apply [5], and this trial may have been too small to 
properly quantify risk of cancer at specific sites. 
 Clinical evidence suggests that there may be a link between 
use of exogenous insulin and risk of cancer at some sites but 
results are conflicting and inconclusive. The CAncer Risk and 
INsulin analogs (CARING) project aims to assess possible 
carcinogenic effects of insulin use combining data from health 
care databases in six European countries. As part of the 
CARING project, the present review and meta-analysis was 
undertaken to summarize published results on the topic. 
Objective 
 To perform a systematic review and meta-analysis of 
published cohort and case-control studies that examined the 
risk of any type of cancer associated with use of exogenous 
human insulin or insulin analogs in patients with type 1 or 
type 2 diabetes. 
METHODS 
Protocol and Registration 
 The present study was developed according to the 
PRISMA guidelines [18], and supplemented by guidance 
from the Cochrane Collaboration Handbook [19]. The 
protocol was registered on Prospero (registration number 
CRD42012002428) [20]. 
Eligibility Criteria 
 The following PICOS eligibility criteria were applied: 
Population: diabetes patients. 
Exposure: diabetes patients using any exogenous human 
insulin or insulin analogues. 
Comparison: diabetes patients, with or without use of 
antidiabetic drugs (i.e. use other types of insulin, non-insulin 
antidiabetic drugs, not use any insulin, or not use any 
antidiabetic drugs). Studies that only had persons without 
diabetes as comparator group were excluded. 
Outcome: incident cancer at specific sites or cancer at any 
site as a composite outcome. Studies that only report the risk 
of cancer-related mortality are not included. 
Study design: cohort and case-control studies. 
 The studies had to report sufficient data for proper 
evaluation of the study population, exposure, comparator and 
outcome to be considered for inclusion in the present review. 
Information Sources 
 We performed a systematic literature search in 5 
databases: Medline at PubMed, Embase, Scopus, Web of 
Science and The Cochrane Library. The last search was 
performed on 27 November 2012. The CARING project 
group concurrently performed a systematic review on risk of 
cancer in persons with diabetes compared to persons without 
diabetes [21]. Records from that review were assessed for 
inclusion in the present review. 
Search Strategy 
 The specific search strategy for each database is 
presented in Supplementary Material 1. Search terms for 
diabetes, insulin and cancer (or similar terms) were applied 
in all searches, while terms for risk or incidence were added 
in free text searches. For Scopus and Web of Science, free-
text searches were used. For Medline, Embase and Cochrane, 
we used thesaurus (MESH and Emtree terms). In addition, 
we performed a free text search in Medline, Embase and 
Cochrane Library limited to references published during the 
last year in order to identify references not yet indexed with 
MESH and Emtree terms. Except for limiting the free text 
search to publications from the last year, no restrictions were 
used on publication date, language or publication status. 
Study Selection and Collection Process 
 ØK and VH developed the search strategy for each 
database in collaboration with a research librarian. ØK 
performed the final search in the databases, compiled a 
mutual reference list for all searches and removed duplicate 
references. ØK and JSL independently screened title and 
abstract of records for eligibility, and records identified by 
either of the reviewers as eligible for inclusion were 
retrieved in full text. If a conference abstract was deemed 
eligible for inclusion, a full text article was searched for in 
databases and included for full text reading if found. ØK and 
JSL independently assessed the full text records for inclusion 
and records that ØK and JSL agreed on were included in the 
review. Disagreements were resolved by discussion and by 
conferring with a third reviewer (PV). 
Data Items 
 From each study, information was retrieved on risk of 
cancer, cancer site, definitions of exposure and comparator 
group (reference), covariates, study design, source 
population, data sources, and patient characteristics 
including diabetes type, age group and geographical location 
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(country). Data was extracted by ØK and validated by JSL 
and disagreements were resolved by discussion. 
Risk of Bias in Individual Studies 
 Risk of bias was assessed by the Newcastle Ottawa Scale 
(NOS) [22]. All studies were scored by two reviewers (ØK, 
JSL) and disagreement resolved by discussion and by 
conferring a third reviewer (PV). The user-defined items 
required in the NOS score were defined as follows 
(Supplementary Material 2): age was the most important 
adjustment factor, the exposed in cohorts should be 
representative of the average “diabetic population using 
insulin”, minimum average exposure duration was 5 years, 
and loss to follow-up less than 10%. A conservative 
approach was chosen if information to score specific items 
were not available in the article, i.e. no points were given on 
an item if information was uncertain or missing. 
Summary Measures and Synthesis of Results (Meta-
Analysis) 
 Initially, the types of exposure-comparator contrasts and 
cancer sites examined in records included in the systematic 
review were assessed by inspecting the summary tables 
(Supplementary Material 3). The contrasts can be 
categorized as: 1) insulin use versus no insulin use; 2) insulin 
use versus use of non-insulin antidiabetic drugs; 3) users of 
insulin A versus users of insulin B; and 4) users of insulin A 
versus users of insulin B or no insulin. Studies that examined 
contrast 1 and 2 were included in the pooled analyses while 
contrast 4 was omitted because of few populations. For 
contrast 3, glargine insulin users versus non-glargine insulin 
users was the most frequently used contrast and was 
included in pooled analyses. 
 Separate pooled analyses were performed for each 
combination of cancer site and exposure contrast (three 
selected) that had more than one study population available. 
One study could contribute more than one population to an 
analysis, e.g. if the presented risk estimate in the original 
study was stratified by gender. For studies that published 
several risk estimates for the same cancer site and exposure 
contrast (e.g. for different study designs), the following 
algorithm was applied for choosing which estimate to 
include (in order of importance): 1) estimates with prior 
cancer excluded was preferred over estimates adjusted for 
prior cancer: 2) intention-to-treat analysis preferred over 
other designs (e.g. as-treated analysis); 3) exposure 
categorized as exclusive use was preferred (monotherapy, 
e.g. “glargine only” preferred over “glargine and non-
glargine”); 4) estimates without latency period preferred. If 
no decision could be made from this algorithm, reviewer 1 
(ØK) made a final decision on which estimate to include. 
Estimates from statistical models adjusted for more 
covariates were preferred. Risk estimates stratified by dose 
or duration of insulin exposure were not included in pooled 
analyses. 
 Hazard ratio, incidence risk ratio, rate ratio and odds ratio 
as summary measures for the risk of incident cancer with 
95% confidence intervals were retrieved from each study. 
These measures were weighted based on the inverse of the  
 
standard error of the risk estimator from the individual 
studies. Chi square test were used to measure heterogeneity 
across studies. DerSimonian and Laird random effects 
models [23] was used in the main analyses regardless of the 
result of the test for heterogeneity. Additional pooled 
analyses with a fixed effect model were performed if studies 
did not exhibit statistically significant heterogeneity. Data 
were prepared in Microsoft Excel 2010 and analyzed in Stata 
version 8. 
Risk of Bias Across Studies in Meta-Analysis 
 Risk of publication bias across studies was assessed by 
Egger’s regression analysis [24] in Stata version 8. 
RESULTS 
Study Selection 
 The selection process is shown in Fig. (1). Five databases 
were searched and 2,285 records were identified. After removal 
of duplicates and inclusion of 5 records from other sources, 
1,578 records were screened. After screening of title and 
abstract by reviewer 1 (ØK) and reviewer 2 (JSL), 135 records 
were retrieved in full text. 42 records [25-66] were eligible for 
inclusion in the systematic review, while the remaining 93 
records were excluded during full text reading for the following 
reasons: no insulin exposure group (25%), population includes 
non-diabetic patients (24%), only conference abstract available 
(16%), outcome was not incident cancer (12%), duplicate use of 
data from one source (10%), study type (9%), ambiguous or 
insufficient reporting of definitions (5%). For the category 
“duplicate use of data”, records were excluded as they were 
likely to be using the same data as one of the records included in 
the review and study the same cancer site and exposure contrast. 
These excluded records [67-75] and the overlapping records that 
are included are listed in Supplementary Material 7. The records 
[76-80] that were excluded because of insufficient reporting of 
definitions are likely to fulfill the criteria for inclusion in the 
present review but cannot be properly classified. The definition 
of the comparator group was not clearly defined, or 
contradicting information regarding the comparator group was 
found in tables and text of these studies. 
Study Characteristics and Risk of Bias Within Studies 
 Tables 1 and 2 present the characteristics of the studies 
included in the systematic review for cohort and case-control 
studies, respectively. 27 cohort studies [25-51] and 15 case-
control studies (9 nested case-control studies) [52-66] were 
included in the systematic review. 
Risk of Bias Within Studies 
 The NOS score for each study is presented in Tables 1 
and 2. The highest NOS score was 9 and the lowest score 
was 4 (attainable score was 0-9). Among 27 cohort studies, 1 
had NOS 6 and the other 26 studies had NOS score 7-9, i.e. 
of fair quality according to NOS. Among the 15 case-control 
studies, 5 studies had NOS 4-6 and all of these were 
“traditional” case-control studies (i.e. not nested). The other 
case-control studies had NOS score 7-9. 
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Results of Individual Studies 
 In the summary tables all cancer sites are presented 
together (Supplementary Material 3). Several studies have 
more than one risk estimate presented for each cancer site 
and exposure contrast because the study reported results for 
several study designs (e.g. with or without latency period, 
intention-to-treat and as-treated analyses), or reported both 
an overall risk estimate as well as risk by strata of 
dose/duration of insulin exposure. Results of individual 
studies are presented in Supplementary Material 4 separately 
for the site-specific cancers examined and for any cancer as a 
composite outcome. Only the preferred risk estimate for each 
combination of cancer site and exposure contrast according 
to the algorithm given in Methods is presented. 
 Cancer at any site and at the following 13 specific sites 
was examined in more than one study per exposure contrast 
and was eligible for inclusion in pooled analyses: breast, 
prostate, stomach, pancreatic, liver, colorectal, colon, rectal, 
respiratory, bladder, kidney, melanoma, and non-Hodgkin’s 
lymphoma (NHL). The results for these cancer sites 
(Supplementary Material 4) reveals substantial heterogeneity 
of results, as point estimates for risk were spread both above 
and below unity (RR=1) for most cancer sites and exposure 
contrasts. More consistent results (point estimates) may be 
present for the exposure contrast insulin versus no insulin for 
any cancer (3 of 4 populations had point estimate above 
unity, and with statistical significance), pancreas (7 of 8 
populations above unity, 6 significant), liver (5 of 6 
populations above unity, 4 significant), stomach (3 of 3 
populations above unity, 3 significant), respiratory (5 of 6 
populations above unity, 4 significant), bladder (4 of 5 
populations above unity, 1 significant), kidney (4 of 4 
populations above unity, 2 significant), and prostate cancer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Flow diagram for the study selection process (PRISMA). 
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Table 1. Characteristics of Cohort Studies Included in the Systematic Review (27 Records) 
 
Author 
(Country) 
Study 
Design 
Study 
Period 
Data Source 
Population 
Source 
Population 
Diabetes 
Type 
Data Source 
Exposure 
New/ 
Prevalent 
Drug User 
Data Source 
Outcome Covariates NOS 
Blin 2012 
(France) 
[25] 
cohort 2003-2010 
insurance 
database nationwide DM2 
insurance 
database 
(claims) 
new insurance database 
Medication possession 
ratio of insulin; age; 
sex; DM duration; DM 
type; ad drugs; 
comorbidities; all ATC 
codes (1st level);  
8 
Campbell 
2010 (USA) 
[26] 
cohort 1992-2007 
Self-reported 
questionnaire 21 states DM2 
Self-reported 
questionnaire prevalent 
Self-reported 
questionnaire 
sex (separate models); 
age; bmi; physical 
activity; NSAIDs; 
alcohol; family history 
colorectal cancer; 
endoscopy history; 
education;  
6 
Carstensen 
2012 
(Denmark) 
[27] 
cohort 1995-2009 
Diabetes 
register nationwide Unspecified 
Diabetes 
register or 
prescription 
database 
new Cancer register 
age; sex (separate 
models);calendar time; 
date of birth; 
9 
Chang 2011 
(Taiwan) 
[28] 
cohort 2004-2007 
insurance 
database nationwide DM2 
insurance 
database 
(claims) 
new Cancer register 
age; sex; dose of fast-
acting insulin; 
metformin; 
sulfonylurea; alpha-
glucosidase inhibitors; 
tzd; glinides; fast-acting 
insulin; premixed 
insulin; detemir; 
diabetes-related 
complications; 
comorbidities 
inpatients/outpatient; 
statins; aspirin; health 
service utilization; 
outpatient visits 
diabetes; outpatient 
visits non-diabetes; 
examinations various; 
physician 
characteristics; 
initiation year insulin; 
8 
Colhoun 
2009 
(Scotland) 
[29] 
cohort 2002/3-2005 
Diabetes 
register nationwide 
unspecified/ 
DM2/DM1 
(varies by 
analysis) 
Diabetes 
register 
new/ 
prevalent 
(varies by 
analysis) 
cancer register 
and causes of 
death register 
varies by cancer site, 
design and model: prior 
cancer; age; sex; DM 
type; calendar year; 
bmi; hba1c; DM 
duration; smoking; 
diastolic bp; systolic bp; 
deprivation; metformin; 
sulfonlyurea; other oad;  
7/8* 
Currie 2009 
(UK) [30] cohort 2000-? 
Physician 
database nationwide DM2 
Physician 
database 
(prescribed) 
new Physician database 
age; sex; prior cancer; 
smoking; 7/8* 
Fagot 2012 
(France) 
[31] 
cohort 2007-2010 
insurance 
database nationwide DM2 
insurance 
database 
(claims) 
new 
Hospital 
records 
database 
age; sex; DM duration; 
metformin; 
pioglitazone; 
rosiglitazone; 
sulfonylurea; other 
niad; 
8 
338    Current Drug Safety, 2013, Vol. 8, No. 5 Karlstad et al. 
 
 
 
 
(Table 1) contd….. 
Author 
(Country) 
Study 
Design 
Study 
Period 
Data Source 
Population 
Source 
Population 
Diabetes 
Type 
Data Source 
Exposure 
New/ 
Prevalent 
Drug User 
Data Source 
Outcome Covariates NOS 
Ferrara 2011 
(USA) [32] cohort 
1997-
2005 
Diabetes 
register 
Northern 
California Unspecified 
pharmacy 
database 
(dispensed) 
prevalent Cancer register 
age; sex; HbA1c 
(baseline); DM 
duration; oad 
(pioglitazone, other tzd 
(almost exclusively 
troglitazone), 
metformin, insulin, 
sulfonylurea, and other 
oral agents (e.g. 
miglitol, acarbose, 
nataglinide, 
repaglinide)); year 
cohort entry; ethnicity; 
income; smoking; 
creatinine; congestive 
heart failure; new DM 
diagnosis; 
8 
Hemkens 
2009 
(Germany) 
[33] 
cohort 2001-2005 
insurance 
database nationwide Unspecified 
insurance 
database 
(claims) 
new insurance database 
age; sex; dose; oad; 
federal state; year first 
insulin; drug use 
(gastrointestinal agents, 
ACE, antiarrhythmic, 
corticosteroids, 
parathyroid gland 
drugs, cytostatics for 
non-malignant disease); 
8 
Hense 2011 
(Germany) 
[34] 
cohort 2003-2008 
insurance 
database 
Munster 
district DM2 
insurance 
database 
(claims) 
prevalent Cancer register age; sex; DM duration; bmi; 8 
Hsieh 2012 
(Taiwan) 
[35] 
cohort 2000-2008 
insurance 
database 
random 
sample of 
nationwide 
database 
DM2 
insurance 
database 
(claims) 
prevalent insurance database age; sex; 9 
Kostev 2012 
(Germany) 
[36] 
cohort 2000-2011 
Physician 
database 
ns (IMS 
Disease 
Analyzer, 
covers 20 
mill patients) 
DM2 
Physician 
database 
(prescribed) 
prevalent?  Physician database 
age; sex; hba1c; 
cumulative duration 
exposure; private 
insurance status; urban 
location of practice; 
region; Charlson 
Comorbidity Index;  
7 
Lai 2012 
(Taiwan) 
[37] 
cohort 2000-2008 
insurance 
database 
random 
sample of 
nationwide 
database 
Unspecified 
insurance 
database 
(claims) 
prevalent insurance database age; sex; 8 
Lai 2012 
(Taiwan) 
[38] 
cohort 2000-2008 
insurance 
database 
random 
sample of 
nationwide 
database 
Unspecified 
insurance 
database 
(claims) 
prevalent insurance database 
age; sex; obesity; 
pulmonary tuberculosis; 
copd; obesity; 
pneumoconiosis; 
asbestosis; tobacco use; 
8 
Lai 2012 
(Taiwan) 
[39] 
cohort 2000-2008 
insurance 
database 
random 
sample of 
nationwide 
database 
Unspecified 
insurance 
database 
(claims) 
prevalent insurance database 
age; sex; comorbidities 
(cirrhosis, alcoholic 
liver damage, hepatitis 
B, hepatitis C); 
8 
Lind 2012 
(Sweden) 
[40] 
cohort 1985-2007 
Hospital 
records 
database 
ns (17 
hospitals) Unspecified 
Hospital 
records 
database 
prevalent? Cancer register 
age; bmi; time since 
start glargine; last 
insulin dose used; 
smoking 
9 
Ljung 2011 
(Sweden) 
[41] 
cohort 2006/7-2008 
prescription 
database nationwide 
Unspecified/
DM2 
pharmacy 
database 
(dispensed) 
prevalent Cancer register 
age; sex. 
breast cancer: age at 
onset DM; bmi; 
smoking; cvd; age at 
first child; oestrogen;  
8 
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Author 
(Country) 
Study 
Design 
Study 
Period 
Data Source 
Population 
Source 
Population 
Diabetes 
Type 
Data Source 
Exposure 
New/ 
Prevalent 
Drug User 
Data Source 
Outcome Covariates NOS 
Morden 
2011 (USA) 
[42] 
cohort 2006-2008 
insurance 
database nationwide DM2 
insurance 
database 
(claims) 
prevalent insurance database 
age; sex; obesity; 
insulin dose; 
metformin; ethnicity; 
diabetes complications; 
oestrogen; poverty; 14 
Charlson comorbidities; 
tobacco; 
8 
Neumann 
2012 
(France) 
[43] 
cohort 2006-2009 
insurance 
database nationwide Unspecified 
insurance 
database 
(claims) 
prevalent 
Hospital 
records 
database 
age; sex; oad; 8 
Newton 
2012 (USA) 
[44] 
cohort 1992-2007 
Self-reported 
questionnaire 
ns (CPS-II 
Nutrition 
Cohort 
participants, 
1.2 million 
participants) 
DM2 Self-reported questionnaire prevalent 
questionnaire 
verified by 
medical 
records/ cancer 
register/ death 
index 
age; sex; bmi; race; 
smoking; education; 
alcohol;  
7 
Oliveria 
2008 (USA) 
[45] 
cohort 2000-2004 
insurance 
database 
insured 
population 
(covers 42 
million 
individuals) 
Unspecified 
insurance 
database 
(claims) 
prevalent 
insurance 
database (ICD-
9) verified by 
pathology/med
ical records 
age; sex. 
Colorectal cancer: 
history polyps; 
ulcerative colitis; 
Crohn's disease. 
Bladder cancer: 
schistosomiasis; pelvic 
radiation. Liver cancer: 
hepatitis B/C; cirrhosis; 
alcoholism.  
Pancreas cancer: partial 
gastrectomy; chronic 
pancreatitis; dvt; 
dermatomyositis/polym
yositis; alcoholism; 
hepatitis B/C; history 
polyps; 
8 
Redaniel 
2012 (UK) 
[46] 
cohort 1987-2007 
Physician 
database nationwide DM2 
Physician 
database 
(prescribed) 
new ns cohort entry year; geography;  9 
Ruiter 2012 
(Netherlands
) [47] 
cohort 2000-2008 
prescription 
database 
Pharmo 
database from 
community 
pharmacies 
(covers 2.5 
million 
individuals) 
DM2 
pharmacy 
database 
(dispensed) 
new 
Hospital 
records 
database 
age; sex; other insulin; 
calendar time; number 
hospitalisations; 
number of non- DM 
drugs used;  
8 
Suissa 2011 
(UK) [48] 
cohort 
matched 
2002-
2009 
Physician 
database nationwide DM2 
Physician 
database 
(prescribed) 
new/preval
ent (varies 
by 
analysis) 
Physician 
database 
Matching on: birth year; 
calendar time; duration 
prior insulin use. 
Adjust for: age; bmi; 
HbA1c; DM duration; 
duration insulin use; 
history of cancer other 
than breast and nmsc 
cancer; metformin; 
sulfonylurea; tzd; 
smoking; alcohol; 
oophorectomy; hrt; 
statin;  
8 
Tseng 2012 
(Taiwan) 
[49] 
cohort 2005 insurance database 
random 
sample of 
nationwide 
register 
DM2 
insurance 
database 
(claims) 
prevalent insurance database 
age; sex; occupation; 
geography; 8 
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(3 of 3 populations below unity, 2significant). For the 
exposure contrast glargine versus non-glargine insulin use, 6 
of 6 populations had risk estimate above unity for prostate 
cancer but none of the individual risk estimates were 
statistically significant. 
 14 cancer sites were only examined in one study per 
exposure contrast and were not included in pooled analyses: 
leukemia, Hodgkin’s lymphoma (HL), multiple myeloma, 
brain, head-neck, skin, testis, ovarian, uterus, cervical, 
thyroid, oesophagus, gastrointestinal, and lymphoma. 
Results of these studies are presented in Supplementary 
Material 5. 
Synthesis of Results (Meta-Analysis) 
 In total, 34 studies were included in pooled analyses. 
Table 3 presents the results of pooled analyses by random 
effects model for the 14 cancer sites and exposure contrasts 
with sufficient number of studies (populations). Significant 
increased risk of cancer for the exposure contrast insulin 
versus no insulin was found for cancer in pancreas, liver, 
kidney and the respiratory system, and a marginal  
 
significance for stomach cancer. A decreased risk was 
observed for prostate cancer. Non-significant results were 
observed for any cancer, bladder, colorectal, colon, rectal, 
non-Hodgkin’s lymphoma, melanoma and breast cancer. For 
the exposure contrast insulin versus non-insulin antidiabetic 
drugs, significant increased risk of any cancer, pancreatic 
and colorectal cancer was observed, while results for prostate 
and breast cancer were not significant. Glargine use was 
associated with a significantly decreased risk of colon cancer 
compared to non-glargine use breast cancer were marginally 
significant, while any cancer, pancreatic, liver, bladder, 
colorectal, respiratory and prostate cancer was not 
statistically significant. 
 Additional fixed effects models were run for studies that 
did not exhibit significant heterogeneity (p>0.05, Table 3). 
These analyses gave similar results as the random effects 
model except for an even higher risk for pancreatic cancer.  
 8 studies only provided risk estimates by dose or duration 
of exposure [33, 50, 52-55, 60, 66] while other studies 
provided dose or duration risk estimates in addition to 
average risk estimates. However, pooled analyses by dose or  
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Author 
(Country) 
Study 
Design 
Study 
Period 
Data Source 
Population 
Source 
Population 
Diabetes 
Type 
Data Source 
Exposure 
New/ 
Prevalent 
Drug User 
Data Source 
Outcome Covariates NOS 
Van Staa 
2012 (UK) 
[50] 
cohort 
matched 
1997-
2006 
Physician 
database 
nationwide 
(GPRD) DM2 
Physician 
database 
(prescribed) 
new Physician database 
Matching on: age; sex; 
calendar year. 
Adjust for: age; sex; 
bmi; HbA1c; oad; ses; 
smoking; alcohol; 
coronary heart disease; 
coronary 
revascularization; 
hyperlipidaemia; 
hypertension; peripheral 
vascular disease; renal 
impairment; angina; 
ARB; antiplatelet; beta-
blockers; calcium- 
channel blockers; 
diuretics; nitrates; 
NSAIDs; aspirin; 
statins; calendar year; 
(some variables only for 
subset of patients) 
8 
Yang 2010 
(Hong 
Kong) [51] 
cohort 
matched 
1996-
2005 
Diabetes 
register 
nationwide 
(all public 
hospitals) 
DM2 
hospital 
inpatient and 
outpatient 
database 
new 
Hospital 
records 
database 
Matching on: age; 
smoking; propensity 
score. 
Adjust for:  
Specific cancer sites: 
only adjust for hba1c?  
Any cancer: age; DM 
duration; HbA1c; spot 
urinary albumin-to-
creatinine ratio (Ln 
ACR 1); retinopathy; 
metformin; smoking; 
hdl; triglycerides; 
estimated glomerular 
filtration rate (eGFR);  
9 
Abbreviations: ACE, ACE inhibitor; Ad, antidiabetic drugs; ARB, Angiotensin II receptor blocker; ATC, Anatomical Therapeutic Chemical (ATC) classification system for drugs; 
Bmi, body mass index; Bp, blood pressure; Copd, chronic obstructive pulmonary disease; Cvd, cardiovascular disease; DM, diabetes mellitus; DM1, diabetes type 1; DM2, diabetes 
type 2; Dvt, Deep venous thrombosis; Hdl, High-density lipoprotein; Hrt, hormone replacement therapy; Niad, non-insulin antidiabetics; Nmsc, non-melanoma skin cancer; NOS, 
Newcastle Ottawa Scale; ns, not specified; Oad, oral antidiabetics; Ses, socioeconomic status; tzd, thiazolidinedione. 
* NOS vary in analyses depending on whether prior cancer is adjusted or excluded. 
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Table 2. Characteristics of Case-Control Studies Included in the Systematic Review (15 Records) 
 
A
ut
ho
r  
(C
ou
nt
ry
) 
St
ud
y 
D
es
ig
n 
St
ud
y 
Pe
ri
od
 
D
at
a 
So
ur
ce
 P
op
ul
at
io
n 
So
ur
ce
 P
op
ul
at
io
n 
So
ur
ce
 fo
r C
on
tr
ol
s 
A
ge
 G
ro
up
 
M
at
ch
in
g 
V
ar
ia
bl
es
 
D
ia
be
te
s T
yp
e 
D
at
a 
So
ur
ce
 E
xp
os
ur
e 
N
ew
/P
re
va
le
nt
 D
ru
g 
U
se
r 
D
at
a 
So
ur
ce
 O
ut
co
m
e 
C
ov
ar
ia
te
s 
N
O
S 
Bodmer 
2010 (UK) 
[52] 
ca
se
-c
on
tro
l 
ne
ste
d 1994-
2005 
physician 
database 
(GPRD) 
nationwide population (GPRD) 30-79 
index 
date; age; 
sex; 
general 
practice;  
D
M
2 Physician 
database 
(prescribed) 
prevalent Physician database 
bmi; DM duration; 
HbA1c; metformin; 
sulfonylurea; tzd; 
prandial glucose 
regulators; acarbose; 
oestrogen; smoking;  
9 
Bodmer 
2011 (UK) 
[53] 
ca
se
-c
on
tro
l n
es
te
d 
1995-
2009
? 
physician 
database 
(GPRD) 
nationwide population (GPRD) <90 
index 
date; age; 
sex; 
general 
practice; 
years of 
history in 
database 
U
ns
pe
ci
fie
d 
Physician 
database 
(prescribed) 
prevalent Physician database 
bmi; HbA1c; DM 
duration; metformin; 
sulfonylurea; smoking; 
oestrogens; oral 
contraceptives; history 
of 
hysterectomy/endometri
osis/polycystic ovaries; 
9 
Bodmer 
2012 (UK) 
[54] 
ca
se
-c
on
tro
l n
es
te
d 
1995-
2009 
physician 
database 
(GPRD) 
nationwide population (GPRD) <90 
index 
date; age; 
sex; 
general 
practice; 
years of 
history in 
database 
U
ns
pe
ci
fie
d 
Physician 
database 
(prescribed) 
prevalent Physician database 
bmi; DM duration; 
HbA1c; metformin; 
sulfonylurea; smoking; 
aspirin; NSAIDs; statin; 
9 
Bodmer 
2012 (UK) 
[55] 
ca
se
-c
on
tro
l n
es
te
d 
1995-
2009 
physician 
database 
(GPRD) 
nationwide population (GPRD) <90 
index 
date; age; 
sex; 
general 
practice; 
years of 
history in 
database 
U
ns
pe
ci
fie
d 
Physician 
database 
(prescribed) 
prevalent Physician database 
bmi; metformin; 
sulfonylurea; smoking; 9 
Bonelli 
2003 
(Italy) [56] 
ca
se
-c
on
tro
l 
1992-
1996 
hospital 
records 
ns (patients 
from 7 
gastroenter
ology and 
endoscopy 
hospital 
units in 
Northern 
Italy) 
hospital 18-75 ns 
U
ns
pe
ci
fie
d 
Interview prevalent hospital 
age; sex; hospital; 
education; occupation; 
alcohol; smoking; 
5 
Chang 
2012 
(Taiwan) 
[57] 
ca
se
-c
on
tro
l n
es
te
d 
2000-
2007 
insurance 
database nationwide population 30-100 
calendar 
time; age; 
gender; 
follow-up 
duration; 
(treatment 
duration)  
D
M
2 insurance 
database 
(claims) 
prevalent Cancer register 
Glitazones; metformin; 
sulfonylurea; glinides. 
varies by cancer site 
(stepwise selection): 
number of oad; statins; 
aspirin; beta-blockers; 
calcium-channel 
blockers; ACE; ARB; 
alpha-glucosidase 
inhibitors; chronic liver 
disease; chronic kidney 
disease; nephropathy; 
neuropathy; 
retinopathy; peripheral 
vascular disease; 
cerebrovascular disease; 
cvd; depression; chronic 
lung disease; 
8 
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Chang 
2012 
(Taiwan) 
[58] 
ca
se
-c
on
tro
l n
es
te
d 
2000-
2007 
insurance 
database nationwide population 30-100 
index 
date; age; 
sex; dm 
duration 
D
M
2 insurance 
database 
(claims) 
prevalent Cancer register 
sulfonylurea; glinides; 
metformin; tzd; alpha-
glucosidase inhibitors; 
statin; aspirin; beta-
blockers; calcium-
channel blockers; ACE; 
chronic liver disease; 
chronic kidney disease; 
nephropathy; 
cerebrovascular disease;  
8 
Cleveland 
2012 
(USA) [59] 
ca
se
-c
on
tro
l 
1996-
1997 
rapid 
reporting 
system for 
cancer, 
interview 
population 
(Nassau 
and Suffolk 
counties of 
Long 
Island) 
population all age 
D
M
2 
Interview prevalent 
hospital, 
confirmed by 
physician 
records 
bmi; metformin; insulin 
secretagogues 
(sulfonylurea); 
menopausal status; race; 
5 
Fortuny 
2005 
(Spain) 
[60] ca
se
-c
on
tro
l 
1998-
2002 
hospital 
records 
ns 
("centres" 
in 4 cities 
(Barcelona, 
Tortosa, 
Reus and 
Madrid)) 
hospital all age; sex; centre; D
M
2 
interview prevalent 
hospital 
clinical data, 
verified by 
histology, 
immunohisto
chemistry 
test, flow 
cytometry 
age; sex; bmi; ad drugs; 
ses; study centre; 5 
Kawaguchi 
2010 
(Japan) 
[61] 
ca
se
-c
on
tro
l n
es
te
d 
2004-
2008  
hospital 
(hepatitis C 
patients) 
ns (patients 
from 3 
hospitals 
specialized 
for liver 
diseases) 
hospital 40+ no 
D
M
2 
ns prevalent hospital biopsy 
age; sex; bmi; HbA1c; 
prior metastatic liver 
tumour; 
cholangiocellular 
carcinoma; history of 
pancreatic tumour; 
sulfonylurea (gliclazide 
or 
glibenclamide);cirrhosis
; albumin; alcohol?; 
AST; lactate 
dehydrogenase (LDH); 
alkaline phosphatase 
(ALP); platelet count; 
gamma-glutamyl 
transpeptidase? 
7 
Koro 2007 
(USA) [62] 
ca
se
-c
on
tro
l n
es
te
d 
1997-
2004 
insurance 
database 
ns (9 
census 
regions, 30 
different 
healthcare 
plans, 38 
million 
patients 
(IHCIS)) 
population 
(insurance 
database) 
18+ 
age; sex; 
index 
date; 
duration 
follow-up 
in 
database 
D
M
2 insurance 
database 
(claims) 
prevalent insurance database age 9 
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duration was assessed as not feasible because these risk 
estimates were reported for different cancer sites, exposure 
contrasts and exposure definitions (e.g. mean or cumulative 
dose, duration since start exposure or cumulative duration. 
Dose and duration risk estimates were identified for any 
cancer, breast, pancreatic, prostate, liver, colorectal, ovarian, 
lung cancer and lymphoma (Supplementary Material 6). 
Risk of Bias Across Studies 
 Egger’s regression test did not reveal any significant (p 
<0.05) publication bias for any cancer site. 
DISCUSSION 
Summary of Evidence 
 In the present meta-analysis, insulin exposure seems to 
be associated with an increased risk of cancer in pancreas, 
liver, kidney, stomach and respiratory system and decreased 
risk of prostate cancer, when compared to no insulin use. 
Compared to use of non-insulin antidiabetic drugs, insulin 
was associated with increased risk of any cancer, pancreatic 
and colorectal cancer. For users of glargine insulin compared 
to users of non-glargine insulin, a decreased risk of colon 
cancer as well as a marginally significant increased risk of 
breast cancer was observed. However, the results from 
individual studies reveal substantial variation in the reported 
cancer risk for most cancer sites. For 11 cancer sites results 
were only available in one population per exposure contrast. 
 The importance of assessing dose and duration of insulin 
use in addition to the average risk has been revealed in 
several studies observing an increased risk of cancer at 
different sites even in the initial period after treatment 
initiation or switch in therapy [27, 40, 50], and the exposure 
duration may be too short to be a causal factor for the 
occurrence of cancer. In particular, a substantial increased 
risk of pancreas cancer is observed and reverse casualty is 
important to consider for this cancer site. Analyses by 
(Table 2) contd….. 
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Li 2011 
(USA) [63] 
ca
se
-c
on
tro
l (
Po
ol
ed
 3
 ca
se
-c
on
tro
l 
stu
di
es
: M
D
A
C
C;
 S
FB
A
; N
C
I) 
M
D
A
CC
: 2
00
1-
20
08
; S
FB
A
: 1
99
5-
19
99
; N
CI
: 1
98
6-
19
89
. MDACC: 
outpatient 
clinic; 
SFBA: 
cancer 
register(?); 
NCI: 
cancer 
register. 
MDACC: 
ns (one 
tertiary 
referral 
hospital);  
SFBA: 
population-
based;  
NCI: 
population-
based. 
MDACC: 
hospital; 
SFBA, 
NCI: 
population
. 
MDA
CC: 
all; 
SFBA: 
21-85; 
NCI: 
21-79 
age; sex; 
race 
(MDACC
, NCI); 
geography 
(NCI); 
U
ns
pe
ci
fie
d 
Interview prevalent 
MDACC: 
hospital data 
with 
pathological 
confirmation.  
SFBA, NCI: 
cancer 
register. 
age; sex; bmi; oad; race; 
education; smoking; 
alcohol; study site;  
6 
Mizuno 
2013 
(Japan) 
[64] ca
se
-c
on
tro
l 
1999-
2011 
hospital 
records 
ns (DM 
patients 
treated at 
specialized 
DM 
institute) 
hospital all no 
U
ns
pe
ci
fie
d 
ns prevalent 
hospital data, 
verified by 
histology or 
clinical 
course 
sulfonylurea; glinides; 
metformin; tzd; alpha-
glucosidase inhibitors; 
family history with 
DM; statin;  
4 
Vinikoor 
2009 
(USA) [65] 
ca
se
-c
on
tro
l 
2001-
2006 
rapid 
reporting 
system for 
cancer, 
interview 
population-
based (33 
counties in 
North 
Carolina) 
population 40-80 age; sex; race; 
U
ns
pe
ci
fie
d 
Interview prevalent Cancer register 
age; sex; bmi; race; 
family history of 
colorectal cancer; 
NSAIDs; calcium 
intake; education;  
7 
Yang 2004 
(UK) [66] 
ca
se
-c
on
tro
l 
ne
ste
d 1990-
2002 
Physician 
database 
(GPRD) 
nationwide population (GPRD) all 
age; 
calendar 
period; 
duration 
follow-up 
in 
database 
D
M
2 Physician 
database 
(prescribed) 
prevalent 
computerize
d medical 
records 
sex; bmi; DM2 
duration; metformin; 
sulfonylurea; 
cholecystectomy 
history; smoking; 
NSAIDs/aspirin;  
9 
Abbreviations: ACE, ACE inhibitor; Ad, antidiabetic drugs; ARB, Angiotensin II receptor blocker; Bmi, body mass index; Cvd, cardiovascular disease; DM, diabetes mellitus; DM1, 
diabetes type 1; DM2, diabetes type 2; NOS, Newcastle Ottawa Scale; ns, not specified; Oad, oral antidiabetics; Ses, socioeconomic status; tzd, thiazolidinedione. 
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duration of insulin exposure reveal specially high risk with 
shorter durations compared to longer durations [27, 63, 64, 
68]. A similar increased risk is observed in the early period 
after diagnosis of diabetes [63, 81]. This could be a result of 
diabetes as an early sign of pancreatic cancer (protopathic 
bias) or ascertainment bias after diabetes diagnosis. 
 Confounding by severity or indication is a concern in 
pharmacoepidemiological studies, and could be more 
Table 3. Results of Pooled Analyses for Cancer Sites and Exposure Contrasts Examined in More than One Study. DerSimonian 
and Laird Random Effects Model and Fixed Effects Model 
 
Cancer Site Exposure Contrast Number of Populations* Random Effects Model Fixed Effects Model
‡ Heterogeneity† 
     RR [95% CI] RR [95% CI] p 
any insulin vs no insulin 4 1.04 [0.75 , 1.45]   <0.001 
 insulin vs niad 2 1.52 [1.16 , 2.00]   0.043 
  glargine vs non-glargine  7 0.96 [0.83 , 1.10]     <0.001 
stomach insulin vs no insulin 3 1.65 [1.02 , 2.68]   0.002 
 insulin vs niad 1 na -   - 
  glargine vs non-glargine  1 na -     - 
pancreatic insulin vs no insulin 8 2.58 [2.05 , 3.25]   <0.001 
 insulin vs niad 3 3.83 [1.43 , 10.23] 4.37 [2.62 , 5.67] 0.167 
  glargine vs non-glargine  3 1.17 [0.78 , 1.77] 1.12 [0.86 , 1.46] 0.128 
liver insulin vs no insulin 6 1.84 [1.32 , 2.58]   <0.001 
 insulin vs niad 1 na -   - 
  glargine vs non-glargine  2 0.89 [0.64 , 1.24] 0.88 [0.68 , 1.14] 0.203 
kidney insulin vs no insulin 4 1.38 [1.06 , 1.79]   0.002 
 insulin vs niad 0 na -   - 
  glargine vs non-glargine  1 na -     - 
bladder insulin vs no insulin 5 1.09 [0.93 , 1.28] 1.07 [0.98 , 1.17] 0.096 
 insulin vs niad 0 na -   - 
  glargine vs non-glargine  2 1.34 [0.81 , 2.22] 1.32 [0.93 , 1.86] 0.150 
colorectal insulin vs no insulin 7 1.16 [0.87 , 1.55]   <0.001 
 insulin vs niad 2 1.79 [1.36 , 2.36] 1.79 [1.36 , 2.36] 0.474 
  glargine vs non-glargine  4 0.92 [0.75 , 1.13] 0.92 [0.75 , 1.13] 0.742 
colon insulin vs no insulin 5 1.02 [0.92 , 1.13] 1.02 [0.92 , 1.13] 0.675 
 insulin vs niad 1 na -   - 
  glargine vs non-glargine  2 0.71 [0.56 , 0.91] 0.72 [0.58 , 0.89] 0.265 
rectal insulin vs no insulin 6 1.00 [0.85 , 1.17] 1.00 [0.85 , 1.17] 0.565 
 insulin vs niad 0 na -   - 
  glargine vs non-glargine  0 na -     - 
respiratory insulin vs no insulin 6 1.30 [1.14 , 1.47]   <0.001 
 insulin vs niad 1 na -   - 
  glargine vs non-glargine  4 0.99 [0.83 , 1.17] 0.99 [0.83 , 1.17] 0.733 
NHL insulin vs no insulin 4 1.16 [0.83 , 1.62]   0.020 
 insulin vs niad 0 na -   - 
  glargine vs non-glargine  0 na -     - 
melanoma insulin vs no insulin 3 0.99 [0.80 , 1.22] 0.99 [0.81 , 1.20] 0.322 
 insulin vs niad 0 na -   - 
  glargine vs non-glargine  0 na -     - 
prostate insulin vs no insulin 3 0.80 [0.73 , 0.88] 0.80 [0.73 , 0.88] 0.825 
 insulin vs niad 3 1.15 [0.86 , 1.54] 1.15 [0.86 , 1.54] 0.477 
  glargine vs non-glargine  6 1.13 [0.98 , 1.32] 1.13 [0.98 , 1.32] 0.726 
breast insulin vs no insulin 7 0.90 [0.81 , 1.00]   0.033 
 insulin vs niad 4 1.13 [0.88 , 1.45] 1.13 [0.88 , 1.45] 0.862 
  glargine vs non-glargine  9 1.14 [1.01 , 1.29] 1.14 [1.01 , 1.29] 0.059 
Abbreviations: na, not applicable. NHL, non-Hodgkin's lymphoma. niad, non-insulin antidiabetic drugs. NOS, Newcastle Ottawa Scale. 
Underlined estimates indicate statistical significance at 5% level.  
* Some studies contribute more than one population in one analysis, e.g. if results in the original study is only presented stratified by gender. 
‡ Only run for heterogeneous studies (test for heterogeneity p>0.05). 
† Chi square test for heterogeneity. 
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pronounced when comparing a third-line therapy like insulin 
to first line therapies like metformin in patients with type 2 
diabetes [14]. Characteristics of populations receiving these 
two therapies can be substantially different concerning 
diabetes duration, obesity and other factors. This effect may 
be less pronounced for use of specific insulin types 
compared to users of other insulin types, although physician 
preference for specific insulin types cannot be excluded. 
Furthermore, a protective effect from metformin use has 
been reported [6] and this is important to consider when 
insulin is compared to metformin or other oral antidiabetic 
drugs. 
 A few studies presented several results for the same 
comparison but from different study designs, e.g. intention-
to-treat and as-treated analysis, with or without latency 
period, new user design or “prevalent users design”. This 
enable assessment of the impact the choice of study design 
has on results. As an example, Colhoun et al. [29] reported 
results for use of “glargine only” and breast cancer risk that 
were substantially different by study design (range 1.47 to 
3.65). Thus, if a different algorithm for selection of estimate 
to include in the present meta-analysis had been applied, the 
marginally significant results for glargine use and breast 
cancer could have been different. This is likely to apply for 
other comparisons as well. 
 During screening, only 2 randomized controlled trials 
(RCT) that assessed the risk of cancer in diabetes patients 
allocated to receive insulins were identified. The Origin trial 
[17] included 12,537 people with impaired glucose tolerance 
or diabetes type 2 for an average follow-up time of 6.2 years 
to study cardiovascular events as primary outcome. 
Participants were randomly allocated to receive insulin 
glargine or standard care and risk of new or recurrent cancer 
was a secondary outcome. There was no difference in risk of 
any cancer for the glargine group compared to the standard 
care group (Hazard Ratio 1.00 [95% CI, 0.88-1.13]). No 
significant difference in risk was reported for specific cancer 
sites: breast (1.01 [0.60-1.71]), lung (1.21 [0.87-1.67]), colon 
(1.09[0.79-1.51]), prostate (0.94 [0.70-1.26]), melanoma 
[0.88 [0.44-1.75]) or cancer at other sites [0.95 [0.80-1.14]). 
A long-term safety study designed to assess ocular 
complications followed 1,017 persons with type 2 diabetes 
(82). Participants were randomly assigned to insulin glargine 
or NPH insulin with a mean cumulative exposure of 4 years. 
As an additional outcome, malignant neoplasms reported as 
serious adverse events were assessed and occurred in 51 
patients and with relative risk 0.63 [0.36-1.09] for glargine. 
Risk of benign and malignant neoplasms was 0.90 [0.64-
1.26]. 
 Two meta-analyses of RCT data from manufacturer’s 
pharmacovigilance databases were also identified. Home et 
al. [15] analysed data from 12 phase 2-4 RCTs conducted by 
Sanofi-Aventis on insulin glargine versus any active 
comparator (insulin or oral antidiabetics) in type 1 and type 2 
diabetes patients. Included studies were between 4 and 52 
weeks duration except for the study by Rosenstock et al. [82] 
mentioned above, and data in the meta-analysis were 
primarily driven by those data. 10,880 patients were included 
and incident malignant cancer occurred in 91 patients with 
relative risk 0.90 [0.60-1.36] for glargine. Dejgaard et al. 
[16] performed a meta-analysis of 21 Novo Nordisk-
sponsored RCTs of insulin detemir compared to NPH insulin 
(16 trials) or insulin glargine (5 trials) in patients with type 1 
or type 2 diabetes. RCTs of at least 12 weeks duration were 
included, with median exposure to insulin of 24 weeks (max 
115 weeks) in trials of detemir versus NPH insulin, and 51 
weeks (max 64 weeks) in trials of detemir versus glargine. 
Malignant cancer occurred in 21 of 6,644 patients with Odds 
Ratio 2.44 [1.01-5.89] for NPH insulin versus detemir, and 
16 events in 2,049 patients with Odds Ratio 1.47 [0.55-3.94] 
for glargine versus detemir. 
Limitations 
 Potential flaws in observational studies of insulin use and 
risk of cancer have been extensively debated, and the quality 
of studies included in the present systematic review is a 
concern. As a measure of the quality of each study, we used 
the NOS score and most studies could be considered as fair 
to high quality. However, it can be argued that NOS score is 
a crude quality measure. Generally, NOS takes into account 
the quality of the underlying data sources but does not fully 
account for important issues in pharmacoepidemiological 
studies, such as definition of drug exposure and time-related 
biases. For instance, the study by Yang et al. [51] reported a 
substantial decreased risk of cancer for insulin users 
compared to nonusers (HR 0.17 [0.09-0.32]). Potentially 
serious flaws in the study design have been pointed out [13, 
83] but the study was nevertheless scored as NOS 9. 
Potential time-related and other biases of other studies 
included in the present systematic review have been 
discussed [10, 12, 14] and these studies also received high 
NOS scores [30, 33, 52]. Thus, the NOS do not seem to fully 
reflect important aspects of quality of the studies of the 
present review and has low granularity to distinguish studies 
of higher and lower quality. 
 The availability of covariates to adjust for confounding 
varied substantially in included studies (Table 1 and 2). The 
NOS score does to some extent take into account confounder 
adjustment, however, adjustment for age and one other factor 
gave full score on this NOS item. The most important 
cofounders to adjust for may vary by cancer site and a more 
thorough assessment of confounder adjustment is desirable. 
Included studies examined a wide variety of exposures and 
comparators and this is useful for assessing consistency of 
the association of insulin and cancer. However, there were 
too few studies (populations) for most combinations of 
cancer site and exposure contrast to perform pooled analyses, 
and additional subgroup or meta-regression analyses could 
not be performed to assess possible determinants of cancer 
risk such as diabetes type, gender, age, incident or prevalent 
insulin use and study design. Egger’s regression test did not 
reveal any significant publication bias for any cancer site. 
However, the number of studies in each analysis was low 
and the test may not have sufficient power to distinguish 
chance from real asymmetry [19]. Selective reporting was 
observed within some published studies as only the analyses 
with significant results were reported [44, 64, 79]. 
Conclusions 
 The results from individual studies in the present review 
revealed substantial variation in reported risk of cancer 
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associated with use of insulin, and varied by type of 
comparison group for the insulin users. Many studies are too 
small to make any firm conclusions. The pooled analyses 
revealed significantly increased or decreased risk of cancer 
at several sites for insulin users. However, there were few 
available studies in each pooled analysis, and subgroup 
analyses of possible determinants of cancer risk like diabetes 
type was not feasible. It is imperative to consider the data 
quality and conduct of individual studies when interpreting 
these results and the choice of study design in individual 
studies may have an effect on the estimated cancer risk. 
Extensive review of the quality of methods, design and 
conduct of studies was not the aim of the present review. A 
fit-for-purpose system for evaluating the quality of 
pharmacoepidemiological studies would be useful in any 
further evaluation of whether the observed associations can 
be attributed to issues with study design, analysis and low 
quality of data. 
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